Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT 06269, USA.
Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT 06269, USA; Current address: Department of Pharmaceutical Sciences, University of North Texas System College of Pharmacy, Fort Worth, TX 76107, USA.
Int J Pharm. 2021 Jan 5;592:120105. doi: 10.1016/j.ijpharm.2020.120105. Epub 2020 Nov 21.
In situ forming implants are attractive long-acting implant dosage forms due to their: i) ability to control drug release; ii) simple manufacturing process; and iii) minimally invasive administration. In situ forming implants are typically made of a drug, solvent, and a biocompatible polymer that controls drug release. Once injected in the subcutaneous tissue, they form solid depots through solvent/non-solvent exchange and phase separation of the biodegradable polymer (such as poly (lactic-co-glycolic acid), PLGA and poly (lactic acid), PLA). However, the mechanism of implant formation and the changes in their microstructure that determine drug release behavior are not fully understood. Furthermore, there is no standardized in vitro release testing method for in situ forming implants due to limitations in recreating bio-relevant and reproducible implant formation in vitro with controllable implant shape, dimensions and surface-to-volume ratio. In the present study, bio-relevant implant formation was recreated in vitro by testing five different methods to determine their effect on drug release kinetics, reproducibility, and internal microstructure formation. The leuprolide acetate formulation Eligard® was used as a model in situ-forming implant, consisting of lyophilized leuprolide acetate, and PLGA dissolved in N-methyl pyrrolidone. The results revealed that the in vitro implant formation method is a crucial step in the dissolution testing process that significantly impacts the release profile of in situ forming implants. An implant formation method that utilizes dissolvable polyvinyl alcohol (PVA) films allowed for initial drug burst release control by modulating implant dimensions (i.e. surface area) and resulted in reproducible in vitro release profiles. In addition, implant formation was shown to affect the internal microstructure of in situ forming implant and was the main factor controlling the release profile which consisted of an initial release phase followed by a release plateau (lag phase) and then a second erosion-controlled release phase.
i)控制药物释放的能力;ii)简单的制造工艺;和 iii)微创管理。原位形成植入物通常由药物、溶剂和控制药物释放的生物相容性聚合物组成。一旦注入皮下组织,它们通过溶剂/非溶剂交换和可生物降解聚合物(如聚(乳酸-共-乙醇酸)、PLGA 和聚乳酸、PLA)的相分离形成固体药库。然而,植入物形成的机制以及决定药物释放行为的微观结构变化尚未完全了解。此外,由于无法在体外重现与生物相关且可重复的植入物形成,具有可控植入物形状、尺寸和表面积与体积比的原位形成植入物的体外释放测试方法尚未标准化。在本研究中,通过测试五种不同的方法来重现生物相关的植入物形成,以确定它们对药物释放动力学、重现性和内部微观结构形成的影响,从而在体外重现生物相关的植入物形成。醋酸亮丙瑞林制剂 Eligard®被用作原位形成植入物的模型,由冻干的醋酸亮丙瑞林和溶解在 N-甲基吡咯烷酮中的 PLGA 组成。结果表明,体外植入物形成方法是溶解测试过程中的关键步骤,对原位形成植入物的释放曲线有显著影响。利用可溶解的聚乙烯醇(PVA)薄膜的植入物形成方法可以通过调节植入物尺寸(即表面积)来控制初始药物突释释放,并产生可重复的体外释放曲线。此外,植入物形成被证明会影响原位形成植入物的内部微观结构,是控制释放曲线的主要因素,释放曲线由初始释放阶段、随后的释放平台(迟滞阶段)和随后的第二次侵蚀控制释放阶段组成。